Pharmacovigilance (PV) plays a vital role in ensuring patient safety after a medicine’s commercialization. Regulators mandate and oversee PV practices to confirm that medicines remain safe and that their benefits continue to outweigh their risks. While regulatory compliance is a key goal, the true potential of PV extends far beyond it. Therefore, marketing authorization holders (MAHs) should view investment in PV as part of a broader risk-mitigation and patient safety strategy.
Ichelon Pharma blog post discusses why investing in a robust pharmacovigilance (PV) system is a strategic essential and explores its broader, long-term benefits for MAHs.
Why Investment in PV must be a Priority for MAHs?
The two key reasons to invest in PV are:
-
Adapting to changing regulatory and health authority regulations
Regulatory compliance is a major mandate to comply with. But the compliance frameworks, regulations, and regional and global health policies are in constant evolution. Technological advancements, new safety data from studies, and global harmonization efforts frequently drive these changes.
In August 2025, the U.S. Food and Drug Administration (FDA) announced that it now publishes adverse event data in its FDA Adverse Event Reporting System (FAERS) daily rather than quarterly.
With a strong PV system, MAHs can swiftly and confidently adapt to these changes. They can ensure continuous compliance with minimal disruption to ongoing safety surveillance and reporting workflows.
-
Driving innovations through development
The applications of modern PV systems go beyond their fundamental role in signal management. The PV data, especially leveraging real-world data (RWD) and artificial intelligence (AI), offers valuable insights that promote innovation in healthcare. Companies can use this information for product improvement, formulation development, or design a trial to study a new indication of the approved product. Such applications generate new opportunities for MAHs and help them gain a competitive advantage in the market.
Risk Mitigation: The Return on Investment
-
Risk Mitigation: The Return on Investment (ROI)
The ROI of PV is far more than a simple balance sheet entry. The following are the most demonstrable, high-impact advantages that clearly outweigh the cost and extend well beyond mere regulatory adherence:
-
Early Identification of Safety Signals
In PV, early signal detection translates to rapid risk mitigation. MAHs can timely report the events to regulators and take measures like updating labels. This way, patient safety is prioritized while promptly collecting relevant information on the cause and other details of adverse drug reactions (ADRs).
-
Prevention of Serious Adverse Events (SAEs)
Preventing SAEs is crucial for reducing patient harm, minimizing litigation risk, and avoiding other financial and reputational damages. Insights from early PV data enable identification of SAEs like heart attacks and strokes. This allows companies to develop and implement rapid corrective actions such as dosage adjustments, black box warnings, or product withdrawal.
-
Protection of Patient Safety
Patient safety is the core mandate of PV. A well-run PV system ensures that the benefit-risk profile of a medicine remains positive in the target population.
In November 2004, Tysabri, a medicine indicated for the treatment of relapsing forms of multiple sclerosis (MS) was withdrawn following confirmed cases of the rare but severe brain infection, progressive multifocal leukoencephalopathy (PML). It was reintroduced in 2006 under a Risk Evaluation and Mitigation Strategy (REMS). The REMS framework mandates patient enrollment, prescriber monitoring, and the JCV antibody test to stratify the risk of PML.
This case clearly highlights how proactive PV approaches ensure patient safety while still promoting the product’s commercial viability. MAHs that prioritize patient safety foster trust among healthcare providers and patients. In the long term, trust is a key driver of product success and market acceptance.
-
Maintenance of Regulatory Compliance
Regulators like the FDA and the European Medicines Agency (EMA) have significant authority to levy heavy fines if incidents of non-compliance are proved.
In 2012, GSK was alleged to have failed to report safety data on a diabetes drug, Avandia. Reports suggest patients and family members filed more than 50,000 lawsuits against GSK in state and federal courts over Avandia’s side effects. The common side-effects experienced were heart attack, congestive heart failure, liver failure, and death.
The investigation found that the company failed to provide crucial post-marketing data to the regulators. The lawsuit was settled, with GSK agreeing to pay $ 242,612,800 for its misconduct. Several case studies suggest that investing in an active safety surveillance system saves millions in costs.
-
Preservation of Company Reputation
In healthcare, trust and reputation are hard to rebuild. A public safety scare resulting from a PV failure damages the MAH’s reputation. It impacts future product launches, investors’ confidence, and physicians’ willingness to prescribe.
Following allegations of non-compliance with PV obligations, regulators often initiate a thorough investigation. Cooperating with investigations necessitates a substantial investment of company time, resulting in a direct loss of productivity. On the other hand, such developments often translate to immediate or gradual loss of revenue from that product.
A transparent PV system preserves and even enhances a company’s image as a responsible and patient-focused organization.
Potential competitive advantage through safety differentiation
Given the rising drug approval and usage rates, demonstrating superior safety monitoring is crucial for MAHs. A track record of regulatory excellence and effective safety management boosts recognition and helps gain a competitive edge.
Companies can showcase proactive PV competence, like using predictive analytics and maintaining strict compliance, as their core strength. This promotes physicians’ confidence to prescribe the medicine and naturally expands the product’s market penetration.
Conclusion
PV is an opportunity for a strategic, long-term investment rather than a mere regulatory mandate. It enables companies to secure public trust, enhance brand reputation, and generate critical safety intelligence that informs product lifecycle management and successful patient outcomes. To ensure these outcomes, evaluate your current PV approach and upgrade it to ensure both patient safety and sustained business success.